Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials
Pooled result · Risk of developing RAResult — go to the resultRelative risk 0.67 95 % CI 0.51–0.89Authors' conclusion
Abatacept is a promising treatment option for slowing down the development of RA in people who are at high risk. It has a positive safety profile.
Study context
- Population
- Persons at high risk of developing rheumatoid arthritis (RA) in the preclinical phase
- Participants
- 367 persons3 randomized controlled trials (RCTs)
- Comparison
- Abatacept vs placebo
- Outcome
- Risk of developing RA
Methodological detailsCochrane Handbook, PRISMA
- Cochrane Handbook
- PRISMA
Pooled result
As reported in the abstract
Relative risk
0.67
95 % CI 0.51–0.89
P = 0.006
Abataceptvs Placebo
RR 0.67 (95 % CI 0.51–0.89); P = 0.006
Further pooled results
| Outcome | SMD (95 % CI) | P value | |
|---|---|---|---|
| Tender joint count | −0.40 (−0.63 to −0.18) | P = 0.0004 | |
| Functional disability | −1.51 (−1.91 to −1.11) | P < 0.00001 | |
| −2−101Difference (linear scale) |
Pain reduction
- No significant difference
Original publication
Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. Semin Arthritis Rheum. Published 4 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →